Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases
REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically relevant outcome measures
Related Questions
How will the positive REYOBIQ trial results affect Plus Therapeutics' revenue forecasts and valuation multiples?
What are the regulatory pathways and expected timeline for FDA approval of REYOBIQ in leptomeningeal metastases, and how might that influence near‑term price volatility?
How does the 75% clinical benefit rate compare to existing therapies and pipeline competitors, and what impact could this have on market share and partnership opportunities?